MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Biogen Company Profile (NASDAQ:BIIB)

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 8 Hold Rating(s), 18 Buy Rating(s)
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $348.76 (23.33% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Robert W. BairdReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Leerink SwannReiterated RatingPositive$319.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Piper JaffrayReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016Goldman SachsReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Citigroup Inc.Reiterated RatingBuy$345.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyLower Price Target$419.00 -> $404.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016BMO Capital MarketsInitiated CoverageMarket Perform$283.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016HC WainwrightReiterated RatingBuy$360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016JPMorgan Chase & Co.Reiterated RatingOverweight$403.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016BarclaysReiterated RatingBuy$420.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells FargoReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit SuisseInitiated CoverageNeutral$322.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Standpoint ResearchInitiated CoverageBuy$360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Raymond JamesReiterated RatingBuy$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2015RBC CapitalReiterated RatingBuy$450.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2015OppenheimerReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Sanford C. BernsteinUpgradeMarket Perform -> Outperform$436.00 -> $385.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2015Bank of AmericaUpgradeNeutral -> Buy$391.23 -> $466.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/29/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha